Aimmune Therapeutics expects to know by the end of March whether the Food and Drug Administration will proceed with review of its peanut allergy treatment, the company said Thursday, clearing up some lingering confusion regarding the drug's regulatory status.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,